GoodRx (GDRX)
(Delayed Data from NSDQ)
$6.60 USD
-0.33 (-4.76%)
Updated May 10, 2024 04:00 PM ET
After-Market: $6.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
GDRX 6.60 -0.33(-4.76%)
Will GDRX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for GDRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GDRX
GoodRx (GDRX) Reports Q1 Earnings: What Key Metrics Have to Say
GoodRx Holdings, Inc. (GDRX) Misses Q1 Earnings Estimates
GDRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Premier, Inc. (PINC) Q3 Earnings and Revenues Surpass Estimates
Countdown to GoodRx (GDRX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Is GoodRx (GDRX) Outperforming Other Medical Stocks This Year?
Other News for GDRX
GoodRx Holdings Inc (GDRX) Q1 2024 Earnings: Navigates Market Challenges with Strategic Adjustments
Solid Performance and Growth Potential Secure GoodRx a Buy Rating Despite Market Overreaction
GoodRx Holdings (GDRX) Receives a Hold from RBC Capital
GoodRx Holdings (GDRX) Gets a Buy from Barclays
GoodRx Holdings: Strong Q1 Performance and Upward Financial Guidance Justify Buy Rating